PETERLABS HOLDINGS BHD

KLSE: 0171 (PLABS)

最近更新时间: 19 Sep, 5:51PM

0.270

0.01 (1.89%)

前收盘价格 0.265
收盘价格 0.260
成交量 5,200
平均成交量 (3个月) 1,405,070
市值 74,307,752
市盈率 (P/E TTM) 27.00
价格/销量 (P/S) 0.410
股市价格/股市净资产 (P/B) 0.950
52周波幅
0.170 (-37%) — 0.550 (103%)
营业毛利率 1.61%
营业利益率 (TTM) 3.89%
稀释每股收益 (EPS TTM) 0.010
季度收入增长率 (YOY) -2.00%
季度盈利增长率 (YOY) -9.50%
总债务/股东权益 (D/E MRQ) 18.61%
流动比率 (MRQ) 2.22
营业现金流 (OCF TTM) 9.51 M
杠杆自由现金流 (LFCF TTM) -3.35 M
资产报酬率 (ROA TTM) 2.47%
股东权益报酬率 (ROE TTM) 3.86%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (MY) 混合的 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看涨 看涨
股票 PLABS - -

AIStockmoo 评分

0.0
分析师共识 0.0
内部交易活动 NA
价格波动 1.0
技术平均移动指标 2.5
技术振荡指标 -3.5
平均 0.00

相关股票

股票 市值 DY P/E(TTM) P/B
PLABS 74 M - 27.00 0.950
DPHARMA 1 B 2.59% 16.88 1.80
KOTRA 632 M 5.99% 14.69 2.23
YSPSAH 298 M 5.24% 14.00 0.710
RHONEMA 144 M 3.82% 16.38 0.850

Peterlabs Holdings Bhd is a Malaysia-based company engaged in the manufacturing, distribution, and trading of animal health and nutrition products. It also provides solutions like farm management, technical advisory services, raw material analysis, and feed formulation. The operating segments of the group are Manufacturing which relates to the manufacturing of animal health and nutrition products, and Trading which relates to the trading and distribution of animal health and nutrition products. It offers products like animal feed additives, veterinary pharmaceuticals, injectable products, multi-nutrient and supplements, topical dressings, cleansing agents, and other related products. The company operates in Malaysia and internationally and generates key revenue from the Trading segment.

部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Value
内部持股比例 74.32%

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
29 Aug 2025 公告 Consolidated results for the financial period ended 30/06/2025
19 Aug 2025 公告 MATERIAL LITIGATION
05 Aug 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - MR BU YAW SENG
04 Aug 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - MR BU YAW SENG
31 Jul 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - MR BU YAW SENG
25 Jul 2025 公告 PETERLABS HOLDINGS BERHAD ("PETERLABS" OR "COMPANY") - MEMORANDUM OF AGREEMENT BETWEEN OSMOSIS NUTRITION SDN BHD AND UNIVERSITI MALAYSIA SABAH
25 Jul 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - NUTRA LIPIDS HOLDINGS SDN BHD
24 Jul 2025 公告 Change in Nomination and Remuneration Committee - DATO HAJI WARNO BIN DOGOL
24 Jul 2025 公告 Change in Audit Committee - DATO SRI MOHD SHAFIQ BIN ABDULLAH
18 Jul 2025 公告 PETERLABS HOLDINGS BERHAD ("COMPANY" OR "PLABS") - APPOINTMENT OF EXTERNAL AUDITORS
15 Jul 2025 公告 MATERIAL LITIGATION
11 Jul 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - NUTRA LIPIDS HOLDINGS SDN BHD
10 Jul 2025 公告 Originating summons at the Kuala Lumpur High Court against the Company and its subsidiaries, Peterlabs Sdn Bhd and Thye On Tong Trading Sdn Bhd ("Summon")
09 Jul 2025 公告 Changes in Sub. S-hldr's Int (Section 138 of CA 2016) - NUTRA LIPIDS HOLDINGS SDN BHD
08 Jul 2025 公告 MATERIAL LITIGATION
07 Jul 2025 公告 Notice of Interest Sub. S-hldr (Section 137 of CA 2016) - NUTRA LIPIDS HOLDINGS SDN BHD
显示更多
5年平均股息收益率 1.89%
股息支付比率 38.83%
除息日 公告日期 支付日期 详情
21 Mar 2024 06 Mar 2024 29 Mar 2024 0.004 现金
14 Jul 2022 20 Jun 2022 22 Jul 2022 0.006 现金
01 Oct 2020 17 Sep 2020 09 Oct 2020 0.01 现金

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2024 0.004 1 2.11
2022 0.006 1 3.08
2020 0.010 1 4.26

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票